The Digest LabA daily digest of news releases

Biotech & Pharma · Week of Nov 2, 2026

Johnson & Johnson, Eli Lilly report ACR data: the week in biotech & pharma

Hengrui Pharma, Braveheart Bio, AbbVie and Q32 Bio also reported; much of the week's data came at ACR Convergence, AHA and ASDS, with GLP-1 deals a second theme.

· The Digest Lab newsroom

Much of the week's news was timed to ACR Convergence 2026 in Orlando. Johnson & Johnson reported Phase 3 results for its oral peptide ICOTYDE (icotrokinra) in psoriatic arthritis and patient-experience findings for nipocalimab in Sjögren's disease. Eli Lilly and Company said it will present retatrutide data in knee osteoarthritis pain with obesity and Taltz plus Zepbound results in psoriatic arthritis with obesity. Other medical meetings also drew data: Hengrui Pharma and Braveheart Bio presented cardiomyopathy results at the American Heart Association Scientific Sessions, and AbbVie's Allergan Aesthetics presented at the American Society for Dermatologic Surgery meeting.

GLP-1 medicines were a second thread. Lilly announced an agreement with Hims & Hers under which patients prescribed Zepbound or Foundayo on that telehealth platform can buy them at Lilly's self-pay prices. Allergan Aesthetics reported studies of facial aesthetic treatment in people taking GLP-1 drugs. On the regulatory side, Johnson & Johnson said the FDA granted accelerated approval to RYBREVANT FASPRO in head and neck cancer, and Q32 Bio reported third-quarter results with plans for a registration-directed program in alopecia areata.

  1. Johnson & Johnson

    Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer

    Johnson & Johnson said on Nov. 5, 2026 that the U.S. FDA granted accelerated approval to subcutaneous RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) as a single agent for recurrent or metastatic head and neck squamous cell carcinoma after platinum-based chemotherapy and an anti-PD-(L)1 antibody. The approval rests on 102 patients in the Phase 1b/2 OrigAMI-4 trial, which showed a 42 percent confirmed overall response rate, with serious adverse reactions in 39 percent and fatal adverse reactions in 6 percent; the company says it is the first dual EGFR and MET-targeted therapy approved in this setting.

  2. AbbVie

    Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications

    Allergan Aesthetics, an AbbVie company, reported results from two Phase 4 studies, HARMONY IN DIVERSITY and HALO, of aesthetic treatment in adults on GLP-1 medications, presented at the 2026 ASDS Annual Meeting. The company says FACE-Q Satisfaction With Facial Appearance improved by a mean of 42.4 points in a 30-patient cohort and by 39.6 points in an interim analysis of 25 HALO participants, with most treatment-related adverse events mild and nonserious.

  3. Eli Lilly and Company

    Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity

    Eli Lilly and Company will present Phase 3 retatrutide data in knee osteoarthritis pain and obesity, along with Phase 3b results for Taltz plus Zepbound in psoriatic arthritis and obesity, at ACR Convergence 2026, held Nov. 6-11. Lilly says retatrutide reduced WOMAC pain by up to 4.5 points (75.8%) in the 68-week TRIUMPH-4 trial, and that 43.7% of patients on Taltz plus Zepbound reached ACR50 at Week 52 in TOGETHER-PsA, compared with 15.7% on Taltz alone.

  4. Eli Lilly and Company

    Lilly and Hims & Hers expand access to FDA-approved Lilly medicines

    Eli Lilly and Company and Hims & Hers Health announced on Nov. 6, 2026 that eligible patients prescribed Zepbound or Foundayo on the Hims & Hers platform can obtain the drugs at Lilly's self-pay prices, starting at $299 and $149 per month respectively. Hims & Hers has committed not to offer compounded copies of Lilly's GLP-1s, and the release does not state a specific start date.

  5. Johnson & Johnson

    Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide

    Johnson & Johnson said on Nov. 7, 2026 that its once-daily oral drug ICOTYDE (icotrokinra) met the primary endpoint in the Phase 3 ICONIC-PsA 1 study in biologic-naive adults with active psoriatic arthritis, with 58% reaching ACR20 at Week 16 versus 41% on placebo. The company says it found no new safety signals through Week 24; ICOTYDE is approved in the U.S. for moderate-to-severe plaque psoriasis but not for psoriatic arthritis.

  6. Q32 Bio

    Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

    Q32 Bio reported a third-quarter 2026 net loss of $8.9 million and cash and cash equivalents of $289.6 million as of September 30, 2026, up from $48.3 million at the end of 2025 after a July offering with gross proceeds of about $200.0 million. The company says it expects to begin a registration-directed program of bempikibart in severe or very severe alopecia areata in the first half of 2027, subject to regulatory discussions planned for the fourth quarter of 2026.

  7. Braveheart Bio, Inc.

    Hengrui Pharma and Braveheart Bio Present Data from52-Week Open-Label Extension of Phase 2 Studyof HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026

    Hengrui Pharma and Braveheart Bio presented 52-week open-label extension data for the cardiac myosin inhibitor HRS/BHB-1893 in obstructive hypertrophic cardiomyopathy at AHA Scientific Sessions 2026 on November 6, 2026. The companies report that 79% of 42 patients had a Valsalva LVOT gradient below 30 mmHg at Week 52 and that there were no on-treatment severe or serious adverse events, though two patients had transient LVEF reductions below 50%.

  8. Johnson & Johnson

    Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients

    Johnson & Johnson announced patient-experience findings from the Phase 2 DAHLIAS study of nipocalimab in Sjögren's disease, in which mouth dryness was the symptom patients most wanted improved. In exit interviews with 49 of 163 participants, 73.5% reported being satisfied or very satisfied with study treatment; the company says Phase 3 studies are ongoing and nipocalimab holds FDA Breakthrough Therapy and Fast Track designations in this disease.

This roundup is written with AI assistance from the press releases listed above, using only what they state. The releases are the companies' own announcements, not The Digest Lab reporting.